Within the Pharmaceutical Cannabis Market , pain management holds the largest share, reflecting the widespread use of cannabis for treating chronic pain. According to the Wise Guy Reports analysis, this segment was valued at USD 6.0 billion in 2024 and is projected to grow to USD 14.0 billion by 2035. The dominance of pain management is driven by the opioid crisis, which has highlighted the need for safer, non-addictive alternatives for chronic pain relief. Cannabis has been shown to be effective for neuropathic pain, inflammatory pain, and pain associated with conditions such as fibromyalgia and arthritis. Patients increasingly prefer cannabis over opioids due to its lower risk of addiction and overdose.

While pain management leads, neurological disorders and cancer treatment are the fastest-growing segments. The neurological disorders segment is experiencing steady expansion as more research establishes the efficacy of cannabis compounds in treating conditions such as epilepsy, multiple sclerosis, and Parkinson's disease. The FDA approval of Epidiolex, a CBD-based drug for rare forms of epilepsy, has been a landmark event, validating the pharmaceutical potential of cannabinoids. The segment's growth is also driven by the increasing prevalence of neurological disorders globally.

Cancer treatment represents another significant application. Cannabis is used to manage cancer-related symptoms, including pain, nausea, vomiting, and appetite loss, often associated with chemotherapy. Evidence also suggests that cannabinoids may have anti-tumor properties, though more research is needed. The growing number of cancer patients and the focus on improving quality of life are driving demand for cannabis-based supportive care.

Mental health disorders is an emerging application area. Cannabis is being studied for its potential to treat anxiety, post-traumatic stress disorder (PTSD), and depression. While the evidence is still evolving, the growing acceptance of cannabis for mental health conditions is creating new opportunities. The compassionate use of cannabis for managing mental health challenges is gaining traction among healthcare professionals and patients.

The growth across these application segments is driven by the increasing recognition of cannabis as a legitimate therapeutic option, the rising prevalence of the conditions it treats, and the ongoing research into its efficacy and safety. As more clinical evidence emerges and regulatory barriers fall, the pharmaceutical cannabis market is expected to expand into new indications, further diversifying its application landscape.